The Hong Kong Private Equity team advised FountainVest Partners in connection with the acquisition of China-based Beijing Zhendong Langdi Pharmaceutical Co., Ltd. for approximately US$900 million. FountainVest is now the controlling shareholder in Langdi Pharmaceutical.
FountainVest Partners is one of the largest private equity funds dedicated to China, with investments in consumer, media, and technology, healthcare, and financial services in Greater China.
Langdi Pharmaceutical is a China-based pharmaceutical company mainly active in the production and supply of calcium supplements for children, pregnant and lactating women, menopausal women, and elderly people, to help prevent and treat osteoporosis, which are registered as over-the-counter (OTC) products.
The Goodwin team was led by partners Victor Chen and Douglas Freeman, associate Eugena Tong and legal consultant Cecilia Chen.